Since April 1 and October 1, 2021 there is a reimbursement of respectively Larotrectinib (Vitrakvi ®) and Entrectinib (Rozlytrek) by the RIZIV/INAMI. Larotrectinib and Entrectinib are used to treat adult and/or pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion which cannot be treated satisfactorily with the available treatment options.

The target group is defined as follows:

  • patients with Belgian health Insurance
  • with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation
  • of which the tumor is locally advanced or metastatic, or the surgical resection is likely to result in severe morbidity
  • that do not have satisfactory alternative treatments
  • after approval by a multidisciplinary oncology consultation (MOC)


The reimbursement can be granted based on an electronic application via the eHealth platform.

 This reimbursement is linked to a mandatory registration of tumor and outcome-specific variables via the Belgian Cancer Registry. There are 3 registration time points:

  • At the latest 1 month after the eHealth application for the NTRK-inhibitor treatment: registration form
  • At the latest 6 months after the end of the NTRK-inhibitor treatment: registration form
  • If the patient is still being treated with Larotrectinib on September 15, 2023: registration form
  • If the patient is still being treated with Entrectinib on March 15, 2024: registration form


Detailed information about these specific requested variables and some 'Frequently Asked Questions' are available in the project manual.


Registrations can be submitted from 01/04/2021 via the Web Based Cancer Registration (WBCR) application of the Belgian Cancer Registry (project module "NTRK-inhibitor"). More information about the usage of this application is available in the WBCR manual.


If you would like more information about the NTRK-inhibitor registration project, please contact us via NTRKinhibitor@kankerregister.org or via 02/212 08 55.